August 20-22, 2019
Boston, MA

Advance the Next Generation of Safe & More Effective Therapies for Bleeding Disorders

With the recent Hemlibra approval and the gene therapy revolution, we are seeing a much needed race to innovate more effective, long-lasting and curative therapies for hemophilia and acquired bleeding disorders.

As such, the 2nd Annual Hemophilia Drug Development Summit remains dedicated to helping large pharma and biotech overcome translational research hurdles and deliver patients more clinically effective therapies and treatment solutions that dramatically improve patient outcomes and quality of life.

Learn from the strategic approaches taken by leading industry experts to:

Picture1

Evaluate the impact of novel products in a changing hemophilia treatment paradigm

Picture1

Optimize the clinical development of novel non-factor, factor replacement products and gene therapy

Picture1

Explore patient advocacy and engagement strategies to better educate patients about new technologies

Picture1

Gain insight into payer and reimbursement strategies for costly gene therapy

"I really enjoyed all of the clinical information presented, it gave me great insight into the pipeline which will help my company prepare for what is to come in this field."

2018 past attendee from Prime Therapeutics


"This was a great networking opportunity and the additional value of some excellent talks was a great benefit."

2018 past attendee from Machaon Diagnostics


"Outstanding conference!"

2018 past attendee from the National Hemophilia Foundation


"Great meeting flow. The opportunity to network was very beneficial."

2018 past attendee from CSL Behring